Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Recurrent Osteosarcoma

Inclusion Criteria

• Patients must have recurrent OS; OS must be verified by histopathology review by the site's Department of Pathology; (patients registered at Memorial Sloan-Kettering [MSK] must have pathology confirmed by MSK Department of Pathology)
• Patients must be in a >= 2nd complete remission as indicated by appropriate radiologic evaluations at the time of study entry
• Patients must be > 1 year of age and =< to 40 years of age at the time of enrollment
• Prior therapy: >= 3 weeks should have elapsed since last cytotoxic therapy, immunotherapy or radiation therapy; more than one week should have elapsed since major surgery * NOTE: Minor surgery (e.g., minor biopsy, central venous catheter placement, shunt revision) is permitted within 1 week prior to enrollment
• Absolute neutrophil count >= 500/ul
• Absolute lymphocyte count >= 500/ul
• Platelet count >= 50,000/ul (transfusion independent)
• Total bilirubin of =< 1.5 times upper limit of normal (exception is made for patients with Gilbert’s syndrome who may be considered eligible if total bilirubin is < 3 times upper limit of normal)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) of =< 3 times upper limit of normal
• Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) of =< 3 times upper limit of normal
• Serum creatinine of =< 1.5 times upper limit of normal
• Shortening fraction of >= 28% or an ejection fraction >= 50%
• No evidence of dyspnea at rest and no history of exercise intolerance
• Eastern Cooperative Oncology Group (ECOG) score of =< 2 or Karnofsky/Lansky score >= 50%
• Prior treatment with other anti-GD2 antibodies is allowed (prior treatment with Hu3F8 is NOT allowed), but human anti-human antibody (HAHA) titer must be negative
• Women of child-bearing potential must be willing to practice an effective method of birth control while on treatment
• Signed informed consent indicating awareness of the investigational nature of this program

Exclusion Criteria

• Patients with OS in first complete remission
• Presence of overt metastatic disease at any site
• Active life-threatening infection
• Pregnant women or women who are breast-feeding
• Inability to comply with protocol requirements